|
|
|
|
| LEADER |
02508nmm a2200445 u 4500 |
| 001 |
EB000390174 |
| 003 |
EBX01000000000000000243227 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
130626 ||| eng |
| 020 |
|
|
|a 9783642328411
|
| 100 |
1 |
|
|a Hübel, Andreas
|
| 245 |
0 |
0 |
|a Limits of Patentability
|h Elektronische Ressource
|b Plant Sciences, Stem Cells and Nucleic Acids
|c by Andreas Hübel, Ulrich Storz, Aloys Hüttermann
|
| 250 |
|
|
|a 1st ed. 2013
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 2013, 2013
|
| 300 |
|
|
|a VIII, 46 p. 2 illus
|b online resource
|
| 505 |
0 |
|
|a Preface -- Andreas Hübel: The Boundaries of Limits - Plant Biosciences -- Ulrich Storz: The Limits of Patentability - Stem Cells -- Aloys Hüttermann: The LImits of Patentability - Genes and Nucleic Acids -- About the Authors
|
| 653 |
|
|
|a Commercial law
|
| 653 |
|
|
|a Plant biotechnology
|
| 653 |
|
|
|a Chemical Bioengineering
|
| 653 |
|
|
|a Plant Biotechnology
|
| 653 |
|
|
|a Medical Genetics
|
| 653 |
|
|
|a Stem cells
|
| 653 |
|
|
|a Medical genetics
|
| 653 |
|
|
|a Stem Cell Biology
|
| 653 |
|
|
|a Biotechnology
|
| 653 |
|
|
|a Commercial Law
|
| 653 |
|
|
|a Biomaterials
|
| 653 |
|
|
|a Nucleic Acid
|
| 653 |
|
|
|a Nucleic acids
|
| 700 |
1 |
|
|a Storz, Ulrich
|e [author]
|
| 700 |
1 |
|
|a Hüttermann, Aloys
|e [author]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a SpringerBriefs in Biotech Patents
|
| 028 |
5 |
0 |
|a 10.1007/978-3-642-32841-1
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-32841-1?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 571.6
|
| 082 |
0 |
|
|a 616.02774
|
| 520 |
|
|
|a SpringerBriefs in Biotech Patents presents timely reports on intellectual properties (IP) issues and patent aspects in the field of biotechnology. In this volume the limits of patentability are addressed, a question that is often raised when it comes to biotechnological inventions: The first section addresses current issues in the patentability of plants produced by essentially biological processes including the controversy between farmer’s privilege and patent exhaustion with respect to seeds in the US. The second section examines the patentability of human embryonic stem cells in Europe and the US, also considering alternative technologies with respect to their practicability and patentability. The third section focuses on the patentability of genes and nucleic acids, especially the issue of patenting of encoding genes and nucleic acids
|